Reviewing Betterware de Mexico SAPI de C (NYSE:BWMX) and Dermata Therapeutics (NASDAQ:DRMA)

Betterware de Mexico SAPI de C (NYSE:BWMX) and Dermata Therapeutics (NASDAQ:DRMA) are both small-cap consumer staples companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Betterware de Mexico SAPI de C and Dermata Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Betterware de Mexico SAPI de C	8.35%	77.89%	11.28%
Dermata Therapeutics	N/A	-166.66%	-130.13%

Earnings & Valuation

This table compares Betterware de Mexico SAPI de C and Dermata Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Betterware de Mexico SAPI de C	$744.00 million	0.80	$55.37 million	$1.83	8.73
Dermata Therapeutics	N/A	N/A	-$7.56 million	($4.39)	-0.33

Betterware de Mexico SAPI de C has higher revenue and earnings than Dermata Therapeutics. Dermata Therapeutics is trading at a lower price-to-earnings ratio than Betterware de Mexico SAPI de C, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

12.7% of Betterware de Mexico SAPI de C shares are owned by institutional investors. Comparatively, 8.7% of Dermata Therapeutics shares are owned by institutional investors. 21.9% of Dermata Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility & Risk

Betterware de Mexico SAPI de C has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, Dermata Therapeutics has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Betterware de Mexico SAPI de C and Dermata Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Betterware de Mexico SAPI de C	1	1	0	1	2.33
Dermata Therapeutics	1	0	1	0	2.00

Dermata Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 584.93%. Given Dermata Therapeutics’ higher probable upside, analysts clearly believe Dermata Therapeutics is more favorable than Betterware de Mexico SAPI de C.

Summary

Betterware de Mexico SAPI de C beats Dermata Therapeutics on 11 of the 14 factors compared between the two stocks.

About Betterware de Mexico SAPI de C

Betterware de Mexico, S.A.B. de C.V. operates as a direct-to-consumer company in Mexico. The company focuses on the home organization segment with a product portfolio, including home solutions, kitchen and food preservation, technology and mobility, and other categories. It serves approximately 3 million households through distributors and associates in approximately 800 communities throughout Mexico. The company was formerly known as Betterware de México, S.A.P.I. de C.V. Betterware de Mexico, S.A.B. de C.V. was founded in 1995 and is based in Zapopan, Mexico. Betterware de Mexico, S.A.B. de C.V. is a subsidiary of Campalier, S.A. de C.V.

About Dermata Therapeutics

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.